Products | July 26, 2010

Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

Related Content

Philips Enters Agreement to Acquire SpectraWAVE
News | Cardiac Imaging
Philips Enters Agreement to Acquire SpectraWAVE

Dec. 15, 2025 — Royal Philips has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in enhanced ...

Time December 18, 2025
arrow
Sponsored Content | Videos | Radiology Business
VIDEO: Talking Trends with Bayer Radiology — Navigating Market Disruptions to Your CT Suite

Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different ...

Time October 09, 2025
arrow
Study: Contrast-Enhanced Ultrasound is Safe, Saves lives
News | Ultrasound Imaging
Study: Contrast-Enhanced Ultrasound is Safe, Saves lives

May 14, 2025 — A comprehensive new study based on nationwide claims data from more than 11 million patients shows that ...

Time May 14, 2025
arrow
Bracco and Blue Earth Diagnostics has announced the appointment of Marco Campione as new CEO, effective immediately. Campione succeeds David Gauden, D. Phil., who now assumes the role of CEO of Bracco subsidiary Blue Earth Therapeutics.
News | Radiology Business
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.
News | Contrast Media
Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
LUMISIGHT and Lumicell Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries
News | FDA
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
Lumicell announced the Medical Imaging Drugs Advisory Committee (MIDAC) of the U.S Food and Drug Administration (FDA) voted in support of the benefit-risk profile of LUMISIGHT
News | Breast Imaging
Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT in the Detection of Cancerous Tissue During Breast Conserving Surgery

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
Lantheus announced that the U.S. Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly.
News | FDA
Lantheus Announces the FDA Approval of DEFINITY as Ultrasound Enhancing Agent for Use in Certain Pediatric Cardiovascular Patients

March 6, 2024 — Lantheus Holdings, Inc. (Lantheus), a radiopharmaceutical company, has announced that the U.S. Food and ...

Time March 06, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now